ALDEN CANCER THERAPY AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO: KH
Karl Henning Kalland1955
Chairman of the board: AH
Anders Haugland1971
Years since formation: 11 years; since Nov 19, 2013
Type: Limited company
VAT registered: Yes
Number of employees: 0

Ownership

Number of shares and share classes: 112; 1 share class
Total number of shareholders: 5; 4 companies, 1 person
Belongs to group of

Financials

Annual total result 2023: -1,853,841; NOK
Total equity 2023: -897,729; NOK

Last update: Aug 29, 2024

Management

Management / administration

Name	Role	Shares
KH Karl Henning Kalland 1955	Managing Director/CEO	17.68 % indirectly

Board

Name	Role	Shares
AH Anders Haugland 1971	Chairman	3.57 % indirectly
BT Bjørn Tore Gjertsen 1966	Deputy Chair	23.57 % indirectly
KH Karl Henning Kalland 1955	Board Member	17.68 % indirectly
AM Anne Margrete Øyan 1949	Board Member	5.89 % indirectly
SK Stener Kvinnsland 1948	Board Member	3.57 % directly

Others

Name	Role	Shares
R RSM NORGE AS	Auditor	-
V VISTNES REGNSKAP AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
BT Bjørn Tore Gjertsen 1966	Deputy Chair	23.57 % indirectly
KH Karl Henning Kalland 1955	Managing Director/CEO, Board Member	17.68 % indirectly
AM Anne Margrete Øyan 1949	Board Member	5.89 % indirectly
PK Phillip Benson Keul 1987	-	5.89 % indirectly
TO Tor Ole Rognaldsen 1981	-	3.57 % indirectly
AH Anders Haugland 1971	Chairman	3.57 % indirectly
SK Stener Kvinnsland 1948	Board Member	3.57 % directly

Last update: Apr 13, 2023

Ownership

Company shareholders

Name	Share class	Number of shares	Share
Y YZ HOLDING AS	Ordinary shares	66	58.93 %
V VESTLANDETS INNOVASJONSSELSKAP AS	Ordinary shares	34	30.36 %
O OCEANVIEW VENTURE CAPITAL AS	Ordinary shares	4	3.57 %
M MARCK INVEST AS	Ordinary shares	4	3.57 %
SK Stener Kvinnsland 1948	Ordinary shares	4	3.57 %

Last update: May 24, 2024

Group structure

YZ HOLDING AS
Total operating income 2023: NOK 29,000
Operating profit 2023: NOK 14,084
Employees: 0

Financials

in NOK

Summary

Year	2023	2022	2021
Total operating income	0	0	0
Annual Total Result	-1,853,841	-984,078	-1,250,086
Total assets	2,867,343	2,756,821	3,081,806
Total liabilities	3,765,073	1,800,710	1,177,617
Total equity	-897,729	956,111	1,904,189

P&L

Year	2023	2022	2021
Total operating income	0	0	0
Total operating costs	1,856,407	987,476	1,248,402
Operating result	-1,856,407	-987,476	-1,248,402
Financial income/costs	2,566	3,398	-1,684
Profit before tax	-1,853,841	-984,078	-1,250,086
Total tax & extraordinary income/cost	0	0	0
Annual Total Result	-1,853,841	-984,078	-1,250,086

Balance overview

Year	2023	2022	2021
Total fixed assets	744,132	1,191,132	1,638,132
Total current assets	2,123,211	1,565,689	1,443,674
Total assets	2,867,343	2,756,821	3,081,806
Short term debt	23,719	59,357	177,617
Long term debt	3,741,353	1,741,353	1,000,000
Total liabilities	3,765,073	1,800,710	1,177,617
Contributed capital	320,684	320,684	284,684
Retained earnings	-1,218,414	635,427	1,619,505
Total equity	-897,729	956,111	1,904,189
Total equity and liabilities	2,867,343	2,756,821	3,081,806

ALDEN CANCER THERAPY AS912 772 438